Cipher Pharmaceuticals (TSE:CPH)
TSX:CPH
Want to see TSE:CPH full AI Analyst Report?
CPH Stock Chart & Stats
C$14.90
C$0.11(0.75%)
At close: 4:00 PM EST
C$14.90
C$0.11(0.75%)
Day’s Range― - ―
52-Week RangeC$11.98 - C$20.56
Previous CloseN/A
Volume17.82K
Average Volume (3M)26.25K
Market Cap
C$422.57M
Enterprise ValueC$301.19M
Total Cash (Recent Filing)C$6.41M
Total Debt (Recent Filing)C$428.30K
Price to Earnings (P/E)9.8
Beta0.47
Next Earnings
Aug 06, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding25,281,181
10 Day Avg. Volume28,238
30 Day Avg. Volume26,255
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.22
Price to Sales (P/S)5.44
P/FCF Ratio9.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$22.00Price Target Upside47.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.88
Revenue Forecast (FY)C$53.46M
Bulls Say, Bears Say
Bulls Say
Exceptional ProfitabilitySustained very high margins (TTM net margin ~54%) indicate durable unit economics and pricing power in core products. High profitability produces internal funding for commercialization or acquisitions, strengthens resilience to cost shocks, and supports long‑term cash generation.
Strong Free Cash Flow And ConversionRobust FCF growth (~77% TTM) and near 1:1 conversion of profit to free cash flow provide ongoing liquidity for reinvestment and deal-making. Reliable cash generation reduces reliance on external capital and supports sustainable funding of commercial expansion and returns.
Conservative Balance SheetVery low leverage (debt/equity ~0.04) and a strengthened equity base leave capacity for selective acquisitions and lower refinancing risk. Healthy ROE in the low-20% range signals efficient capital use, bolstering medium‑term stability and strategic optionality.
Bears Say
Profitability And Earnings VolatilityMaterial year-to-year swings in margins and net income imply earnings are influenced by non-recurring items or portfolio mix shifts. This reduces predictability of recurring profits and complicates multi‑quarter planning, budgeting, and assessment of sustainable margin levels.
Inconsistent Debt LevelsSignificant swings in debt across reporting periods show capital structure can change rapidly. Such inconsistency increases refinancing and interest exposure risk, weakens forecasting of financing costs, and can constrain strategy if leverage rises when liquidity is needed.
Dependence On Partners For International SalesRelying on licensing and commercial partners outside Canada reduces Cipher's control over pricing, market access, and reimbursement. Partner execution variability creates structural revenue and margin uncertainty across geographies and limits visibility into long‑term international growth.
Cipher Pharmaceuticals News
CPH FAQ
What was Cipher Pharmaceuticals’s price range in the past 12 months?
Cipher Pharmaceuticals lowest stock price was C$11.98 and its highest was C$20.56 in the past 12 months.
What is Cipher Pharmaceuticals’s market cap?
Cipher Pharmaceuticals’s market cap is C$422.57M.
When is Cipher Pharmaceuticals’s upcoming earnings report date?
Cipher Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 56 days.
How were Cipher Pharmaceuticals’s earnings last quarter?
Cipher Pharmaceuticals released its earnings results on May 07, 2026. The company reported C$0.332 earnings per share for the quarter, beating the consensus estimate of C$0.187 by C$0.145.
Is Cipher Pharmaceuticals overvalued?
According to Wall Street analysts Cipher Pharmaceuticals’s price is currently Undervalued.
Does Cipher Pharmaceuticals pay dividends?
Cipher Pharmaceuticals does not currently pay dividends.
What is Cipher Pharmaceuticals’s EPS estimate?
Cipher Pharmaceuticals’s EPS estimate is 0.29.
How many shares outstanding does Cipher Pharmaceuticals have?
Cipher Pharmaceuticals has 25,281,181 shares outstanding.
What happened to Cipher Pharmaceuticals’s price movement after its last earnings report?
Cipher Pharmaceuticals reported an EPS of C$0.332 in its last earnings report, beating expectations of C$0.187. Following the earnings report the stock price went up 10.464%.
Which hedge fund is a major shareholder of Cipher Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:CPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cipher Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$22.00 (47.65% Upside)
C$22.00 (47.65% Upside)
Insider Transactions
Sold Shares
Worth C$129.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.29%
12-Months-Change
Fundamentals
Return on Equity
25.69%
Trailing 12-Months
Asset Growth
-6.01%
Trailing 12-Months
Company Description
Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada, operates as a specialized pharmaceutical enterprise. The company markets a diverse portfolio of commercial therapeutic solutions. These include Epuris (CIP-ISOTRETINOIN), formulated for severe acne; Ozenoxacin, targeting impetigo in both adult and pediatric patients; Actikerall, prescribed for palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a topical cream designed to mitigate unwanted facial hair growth in women; BRINAVESS, utilized for restoring sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet medication. Beyond its directly marketed offerings, Cipher's portfolio encompasses various licensed products, such as CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), used in the management of hyperlipidemia, a lipid metabolism disorder; and Conzip/Durela (CIP-Tramadol), indicated for the relief of moderate to moderately severe pain. Looking to the future, Cipher maintains a robust developmental pipeline, which includes Trevyent, a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension; CF-101, under investigation for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for onychomycosis; and DTR-001, a novel cream for tattoo removal.
CPH Company Deck
CPH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and significant debt reduction, supported by the robust performance of the Natroba business. However, challenges remain in licensing revenue and the Absorica portfolio, along with increased SG&A costs. Overall, the positive aspects slightly outweigh the negative aspects.View all TSE:CPH earnings summariesCPH Stock 12 Month Forecast
Average Price Target
C$22.00
▲(47.65% Upside)
Technical Analysis
Knight Therapeutics
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―
Options Prices
Currently, No data available
---